The performance of multinational pharmaceutical companies has generally recovered, and executives may usher in salary increases!

The salary of executives of pharmaceutical companies is a topic of general concern in the industry.
From February to April every year, pharmaceutical companies announce salary adjustments
.
Generally speaking, whether the compensation of executives rises or falls is linked to the performance of the company
.
So far, a number of multinational pharmaceutical companies have disclosed their 2021 financial reports, including more than 10 multinational pharmaceutical companies including Roche, Novartis, Bristol-Myers Squibb, Sanofi, and Merck
.
Overall, the performance of multinational pharmaceutical companies will generally pick up in 2021
.
In this regard, the industry expects that the executives of these companies may usher in salary increases
.
Judging from the above-mentioned public financial reports, pharmaceutical companies have disclosed the company's CEO salary in 2021
.
As shown in Roche's 2021 financial report, the company's CEO Severin Schwan will receive a total salary of 11.
49 million Swiss francs ($12.
48 million) in 2021, including an annual salary of 4 million Swiss francs and a bonus of 8 million Swiss francs
.
At the same time, Schwan also received share appreciation rights worth CHF 3.
38 million, restricted stock units worth nearly CHF 600,000, and other compensation such as pension funds and reimbursement allowances
.
It is understood that driven by factors such as the launch of new drugs and the epidemic, Roche's performance in 2021 will rise significantly, with a total revenue of CHF 62.
801 billion for the year, a year-on-year increase of 9.
3%
.
Among them, the pharmaceutical business revenue was 45.
041 billion Swiss francs, a year-on-year increase of 3.
1%
.
Novartis CEO Vas Narasimhan realized compensation worth 11.
22 million Swiss francs ($12.
18 million) in 2021, an 8% increase from 10.
38 million Swiss francs in 2020
.
The compensation of CHF 11.
22 million includes Vas Narasimhan's performance-based compensation plan, as well as fixed compensation and benefits of approximately CHF 2.
2 million
.
According to the financial report, Novartis' revenue in 2021 will reach US$51.
626 billion, a year-on-year increase of 6%, of which the pharmaceutical business revenue will be US$42 billion, an increase of 8% year-on-year.

.
The company believes that it has achieved several of Narasimhan's long-term goals, thereby securing the payment of Narasimhan's remuneration
.
Novartis' annual growth target was 119% of Narasimhan's long-term performance plan target, and Novartis' core operating income growth was twice Narasimhan's target
.
Separately, Novartis said the company also exceeded Narasimhan's performance plan targets in innovation metrics
.
In addition to Roche and Novartis, Bristol-Myers Squibb, Sanofi, Merck, Eli Lilly and other multinational pharmaceutical companies have also achieved performance growth in 2021.
Although these pharmaceutical companies have not yet disclosed executive compensation Look, the total compensation of the CEOs of Johnson & Johnson, AbbVie, and Eli Lilly has exceeded 20 million US dollars
.
So this year, which multinational pharmaceutical company will have a higher salary adjustment? Some people in the industry believe that it may be useful to analyze the annual performance of multinational pharmaceutical companies in 2021
.
Judging from the data of public financial reports, the top companies in revenue in 2021 include Johnson & Johnson, Pfizer, AbbVie,
etc.
In this regard, the industry expects that these pharmaceutical companies will perform relatively well in 2021, and are likely to become pharmaceutical companies with relatively large executive salary adjustments
.
Of course, this is only a one-sided analysis and can only be used as a reference.
For the specific situation, please look forward to the subsequent disclosure of the major pharmaceutical companies
.
For medical professionals, it is a common pursuit for people to increase their salary.
However, in the context of the ever-changing pharmaceutical market, pharmaceutical companies are also constantly increasing their requirements for talents.
Medical professionals also need to continuously improve their business capabilities.
Actively seek opportunities to gain more room for growth
.